Evamist® offers the most titration choices for a single HRT prescription.
- 3 daily dosing options
- Women can start with the lowest dose and titrate according to their healthcare provider’s direction
- Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
- Healthcare providers can change a patient’s dose without writing a new prescription
Precise, Adjustable Delivery.
1 spray consists of 90 mcL that contains 1.53 mg estradiol.
Evamist® (estradiol transdermal spray) is applied once daily to a small area of skin on the inner forearm.
Because Evamist is a transdermal (delivered through the skin) medication, the estrogen is absorbed through the skin, enters the bloodstream and acts to reduce moderate-to-severe hot flashes.1-3
Evamist is indicated for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.
Evamist has been shown to reduce the frequency and severity of these hot flashes. Hot flashes occurring at night, or night sweats, may be moderate to severe in nature.
For your patients with moderate-to-severe night sweats, consider Evamist.®
In a multiple-dose study, 72 postmenopausal women were treated for 14 days with Evamist to the inner forearm. Serum concentrations of estradiol appeared to reach steady state after 7 to 8 days.
Our applicator makes dosing precise and adjustable.
The Evamist® (estradiol transdermal spray) applicator is designed to release the same dose of estrogen (1.53 mg estradiol) with each 90 mcL spray, so patients always apply a precise amount of medication. The Evamist applicator contains 56 sprays and can be used to deliver 1, 2 or 3 spray doses each day. Treatment with estrogen should be started at the lowest dose possible, and used only for as long as needed to provide relief of moderate-to-severe hot flashes associated with menopause.
Healthcare providers should start each woman at the lowest dose (1 spray) and can easily adjust the dose to 2 or 3 sprays to find the dose that works best.
Young children who are accidentally exposed to estrogen through contact with women using Evamist® (estradiol transdermal spray) may show signs of puberty that are not expected (e.g., breast budding, breast masses, and gynecomastia). In most cases, the condition is resolved with removal of Evamist exposure. Women should ensure that children do not come into contact with the site(s) where Evamist is applied.
- Evamist® (estradiol transdermal spray) Prescribing Information, Perrigo, January 2015.
- Data on file, Perrigo.
- Nachtigall LE. Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Am J Obstet Gynecol. 1995;173:993-997.